Keros Therapeutics Posts Q2 2026 Loss of $1.45/Share, Extends Cash Runway into 2028, and Launches Phase 2 DMD Trial
KROS is trading near its 52-week low of $9.69 (3.4% above the low).
Summary
Keros Therapeutics recorded a Q2 2026 net loss of $28.7M ($1.45/share) and held $257.6M in cash, extending its runway into 2028. The company also initiated a Phase 2 trial for rinvatercept in DMD, with data anticipated in H1 2027.
Key Events · Earnings and Guidance · KROS
-
Q2 2026 Net Loss Widens
The net loss reached $28.7M ($1.45 per share), compared with $30.7M ($0.76 per share) in Q2 2025, as Takeda-related revenue disappeared.
-
Cash Runway Extended to H1 2028
Cash and cash equivalents stood at $257.6M as of June 30, 2026, down from $287.4M at year-end 2025, and are projected to fund operations into the first half of 2028.
-
Phase 2 DMD Trial Initiated
A Phase 2 clinical trial for rinvatercept in Duchenne muscular dystrophy has commenced; initial data are expected in the first half of 2027.
-
Operating Expenses Decline Sharply
R&D expenses dropped to $22.3M from $43.5M in Q2 2025, while G&A fell to $8.6M from $14.5M, reflecting the Takeda transition and the 2025 restructuring.
Analysis · KROS · Life Sciences
A Q2 net loss of $28.7 million, or $1.45 per share, widened from the prior quarter's $1.21 loss as revenue evaporated following the Takeda deal. Operating expenses, however, contracted sharply—R&D nearly halved with elritercept costs shifting to Takeda. With $257.6 million in cash, the company now has a runway into the first half of 2028. Adding to the pipeline momentum, a Phase 2 trial for rinvatercept in DMD has begun, and initial data are expected in the first half of 2027. Given that the stock is hovering near its 52-week low, the extended cash runway and clinical progress are vital for restoring investor confidence.
How filings like this one have moved
In the 30 days to Sep 20, 2026, 29.5% of the 1601 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.41%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KROS was trading at $10.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $200.1M. The 52-week trading range was $9.69 to $22.55. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.